Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9493435 | 1.00 | CYP11B2 (0.43) | CYP11B2TAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL9493247 | 1.00 | CYP11B2 (0.43) | CYP11B2TAS1R3TAS1R1TAS1R2KMT2A | |
| Ethonam SCHEMBL29386266 | 0.88 | CYP19A1 (0.53) | CYP11B2TAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL2820997 | 0.88 | CYP11B2 (0.41) | CYP11B2HSD11B1CYP19A1 | |
| SCHEMBL2820348 | 0.88 | CYP11B2 (0.41) | CYP11B2HSD11B1CYP19A1 | |
| SCHEMBL2820351 | 0.88 | CYP11B2 (0.41) | CYP11B2HSD11B1CYP19A1 | |
| Ethonam SCHEMBL1852062 | 0.88 | CYP19A1 (0.53) | CYP11B2TAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL9496305 | 0.87 | HSD11B1 (0.41) | CYP11B2TAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL9805000 | 0.87 | CYP11B2 (0.46) | CYP11B2TAS1R3TAS1R1TAS1R2KMT2A | |
| SCHEMBL10483522 | 0.86 | CYP11B2 (0.43) | CYP11B2TAS1R3TAS1R1TAS1R2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0207563-B1 | A METHOD FOR CONTROLLING WEEDS | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-31 | — | — | EP | claimed |
| EP-0207563-A2 | A method for controlling weeds | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-01-07 | — | — | EP | claimed |
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2213668-A2 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2094680-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-5246915-A | Herbicides | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-09-21 | — | — | US | disclosed |
| EP-0207563-B1 | A METHOD FOR CONTROLLING WEEDS | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-31 | — | — | EP | disclosed |
| EP-0207563-A2 | A method for controlling weeds | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | CYP11B2 6/4885TAS1R3 4475/4885TAS1R1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.